Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 5/20 | 0.39 |
| ▸ | HTR2A | P28223 | 5/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29370016 | 1.00 | CDC7 (0.46) | CDC7KDRMKNK1NPC1RAB9A | |
| SCHEMBL30177011 | 0.89 | MAOB (0.42) | CDC7KDRMKNK1ALDH1A1MAPT | |
| SCHEMBL21901214 | 0.88 | ROCK2 (0.42) | KDRMKNK1NPC1RAB9AMAPK1 | |
| SCHEMBL29535923 | 0.87 | GRM4 (0.39) | CDC7ALDH1A1MAPTKDM4E | |
| SCHEMBL21901151 | 0.87 | GRM4 (0.39) | CDC7ALDH1A1MAPTKDM4E | |
| SCHEMBL23517422 | 0.85 | CDC7 (0.40) | CDC7KDRMKNK1NPC1RAB9A | |
| SCHEMBL26051477 | 0.85 | HTR2A (0.41) | CDC7KDRMKNK1NPC1RAB9A | |
| SCHEMBL21901171 | 0.84 | CDC7 (0.46) | CDC7KDRMKNK1NPC1RAB9A | |
| SCHEMBL22655796 | 0.83 | PTK2 (0.39) | MKNK1NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL31085391 | 0.83 | PTK2 (0.39) | MKNK1NPC1RAB9AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279010-A1 | PROCESSES FOR PREPARING MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-09-07 | — | — | US | disclosed |
| US-20230279010-A1 | PROCESSES FOR PREPARING MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-09-07 | — | — | US | disclosed |
| US-20230265080-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMA (US) | 2023-08-24 | — | — | US | disclosed |
| US-20230265080-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMA (US) | 2023-08-24 | — | — | US | disclosed |
| US-20230265080-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMA (US) | 2023-08-24 | — | — | US | disclosed |
| CN-116234809-A | Methods of preparing alpha-1 antitrypsin modulators | 弗特克斯药品有限公司 | 2023-06-06 | — | — | CN | disclosed |
| US-20230159580-A1 | PYRROLO[2,3-F]INDAZOLE AND 2,4,5,10-TETRAZATRICYCLO[7.3.0.03,7]DODECA-1,3(7),5,8,11-PENTAENE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| US-20230159580-A1 | PYRROLO[2,3-F]INDAZOLE AND 2,4,5,10-TETRAZATRICYCLO[7.3.0.03,7]DODECA-1,3(7),5,8,11-PENTAENE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| US-11623924-B2 | Modulators of alpha-1 antitrypsin | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-04-11 | — | — | US | disclosed |
| CN-115776984-A | Pyrrolo [2,3-f ] indazole and 2,4,5, 10-tetraazatricyclo [7.3.0.03,7] dodec-1, 3 (7), 5,8, 11-pentaene derivatives as alpha-1-antitrypsin modulators for the treatment of alpha-1 antitrypsin deficiency (AATD) | 弗特克斯药品有限公司 | 2023-03-10 | — | — | CN | disclosed |
| EP-4126877-A1 | PYRROLO[2,3-F]INDAZOLE AND 2,4,5,10-TETRAZATRICYCLO[7.3.0.03,7]DODECA-1,3(7),5,8,11-PENTAENE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | Vertex Pharmaceuticals Incorporated (US) | 2023-02-08 | — | — | EP | disclosed |
| WO-2021203010-A1 | PYRROLO[2,3-F]INDAZOLE AND 2,4,5,10-TETRAZATRICYCLO[7.3.0.03,7]DODECA-1,3(7),5,8,11-PENTAENE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-10-07 | — | — | WO | disclosed |
| WO-2021203010-A1 | PYRROLO[2,3-F]INDAZOLE AND 2,4,5,10-TETRAZATRICYCLO[7.3.0.03,7]DODECA-1,3(7),5,8,11-PENTAENE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-10-07 | — | — | WO | disclosed |
| CN-113164761-A | Modulators of alpha-1 antitrypsin | 弗特克斯药品有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-20210179587-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED | 2021-06-17 | — | — | US | disclosed |
| US-20210179587-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED | 2021-06-17 | — | — | US | disclosed |
| WO-2021067584-A1 | METHODS OF TREATMENT FOR ALPHA-1 ANTITRYPSIN DEFICIENCY | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-04-08 | — | — | WO | disclosed |
| WO-2020247160-A1 | CONDENSED TRYCICLIC PYRROLES AS ALPHA-1 ANTITRYPSIN MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-12-10 | — | — | WO | disclosed |
| US-20200361939-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED. | 2020-11-19 | — | — | US | disclosed |
| WO-2020081257-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279010-A1 | PROCESSES FOR PREPARING MODULATORS OF ALPHA-1 ANTITRYPSIN | SERPINA2, SERPINC1, SERPINE1 | CDC7 4596/4885KDR 4855/4885MKNK1 3751/4885 |
| US-20200361939-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | SERPINA2, SERPINC1, SERPINA3 | CDC7 3618/4885KDR 4851/4885MKNK1 2524/4885 |
| US-20230159580-A1 | PYRROLO[2,3-F]INDAZOLE AND 2,4,5,10-TETRAZATRICYCLO[7.3.0.03,7]DODECA-1,3(7),5,8,11-PENTAENE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINA3, SERPINC1 | CDC7 2641/4885KDR 4758/4885MKNK1 2403/4885 |
| US-11623924-B2 | Modulators of alpha-1 antitrypsin | SERPINA2, SERPINA3, SERPINB1 | CDC7 3537/4885KDR 4870/4885MKNK1 3216/4885 |
| US-20210179587-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | SERPINA2, SERPINA3, SERPINB1 | CDC7 3537/4885KDR 4870/4885MKNK1 3216/4885 |
| US-20230265080-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | SERPINA2, SERPINA3, SERPINB1 | CDC7 3537/4885KDR 4870/4885MKNK1 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.